Health Economics›Soft tissue sarcoma›Locally advanced or metastatic disease single-agent regimens

Locally advanced or metastatic disease single-agent regimens

Soft tissue sarcoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #01	—	R 132 655	28d	~4.3 mo	—	~2	~R 265 310 PFS proxy · indirect	4
Trabectedin monotherapy Variant #01	—	R 103 351	21d	4.4 mo	—	2	R 206 702 PFS proxy	2
Pazopanib monotherapy Variant #01	—	R 22 754	28d	4.6 mo	—	26	R 591 593 PFS proxy	1
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
Temozolomide monotherapy Variant #02	—	R 3 434	14d	~4.0 mo	~16.3 mo	~27	~R 92 712 PFS proxy · indirect	10
Epirubicin monotherapy Variant #01	—	R 3 200	21d	~8.2 mo	~19.1 mo	~7	~R 22 400 PFS proxy · indirect	1
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	—	~13.1 mo	~2	~R 5 217 PFS proxy · indirect	4
Doxorubicin monotherapy Variant #01	—	R 902	21d	~5.4 mo	~19.0 mo	~9	~R 8 114 PFS proxy · indirect	6
Cisplatin monotherapy Variant #01	—	R 588	21d	~1.4 mo	—	~6	~R 3 530 PFS proxy · indirect	1

9 of 9 regimens shown